Is AVBP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.

AVBP (ArriVent BioPharma, Inc. Common Stock) Stock Analysis - Financials

ArriVent BioPharma, Inc. Common Stock (AVBP) is a publicly traded Healthcare sector company. As of November 9, 2026, AVBP trades at $14.27 with a market cap of $672.56M and a P/E ratio of -3.92. AVBP moved +3.70% today. Year to date, AVBP is -31.96%; over the trailing twelve months it is -21.57%. Its 52-week range spans $11.36 to $35.83. Analyst consensus is strong buy with an average price target of $25.55. Rallies surfaces AVBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are AVBP's key financials?

AVBP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AVBP recently traded at $14.27. Market cap is $672.56M. P/E ratio is -3.92. Revenue is $0.

AVBP Key Metrics

Key financial metrics for AVBP
Metric	Value
Price	$14.27
Market Cap	$672.56M
P/E Ratio	-3.92
EPS	$-4.32
Dividend Yield	0.00%
52-Week High	$35.83
52-Week Low	$11.36
Volume	598.20K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-166.31M
Gross Margin	0.00%

AVBP Analyst Consensus

12 analysts cover AVBP: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.55.

Common questions about AVBP

What are AVBP's key financials?: AVBP financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. AVBP recently traded at $14.27. Market cap is $672.56M. P/E ratio is -3.92. Revenue is $0.
Is AVBP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.